Skip to main content

Table 3 Primary and secondary outcomes by trial arm

From: Use of malaria rapid diagnostic tests by community health workers in Afghanistan: cluster randomised trial

Patient level: n, (%)

Intervention n = 1099

Control N = 1055

Risk ratio (95% CI)

p value

Primary outcome

 Appropriate treatment of malaria by CHWsa

828 (75.3)

185 (17.5)

3.72 (2.40–5.77)

<0.001

Secondary outcomes

 Malaria negative patients prescribed antimalarial drug (n = 1875)

95 (10.0)

813 (87.6)

0.11 (0.08–0.15)

<0.001

 P. falciparum malaria cases prescribed an ACT (n = 86)

12 (28.6)

–b

–

 

 P. vivax malaria cases prescribed CQ (n = 346)

70 (45.1)

164 (85.9)

0.43 (0.31–0.59)

<0.001

 Malaria negative patients prescribed co-trimoxazole (n = 1756)

613 (67.2)

295 (35.0)

1.98 (1.18–3.33)

0.012

Referral practices:

 Referral on to formal health services (n = 2399)

414 (34.6)

317 (26.4)

1.53 (0.89–2.63)

0.116

  1. aComposite measure defined against the malaria PCR result for each patient: falciparum or mixed-species malaria treated with SP/AS; vivax malaria treated with CQ (regardless of accompaniment with SP); and PCR-confirmed negative cases receiving no antimalarial drug
  2. bACTs were not used in the control arm, as they can only be prescribed based on parasitological diagnosis. In the intervention arm, N = 42